2018 Speakers

See below for details of speakers who are already confirmed to present at ENDS this June:

  • Chris Allen

    Managing Director Broughton Laboratories

    With over 20 years’ industry experience in the analytical science industry, Chris Allen is the co-founder of Broughton Laboratories and serves as the Managing Director. Chris joined Broughton in 2006 coming from a contract analytical laboratory within the animal health industry. His educational background is a BSc in Chemistry from The University of Hull.

    Originally, Chris began his career as an Analytical Chemist within a global medical technology business specialising in medical devices and wound care products. From there, he has held positions where he gained thorough knowledge of analytical techniques and operational management. Since his appointment as MD in 2011, Chris’ focus is to provide collaborative leadership as well as develop and implement strategic plans that deliver value and unrivalled experiences to customers. Chris’ first involvement in the analysis of electronic cigarettes began in 2009 supporting the development and regulatory programme for e-Voke, the first electronic cigarette to be granted a medicinal license. Since then, Chris and the team at Broughton have worked on numerous projects in support of EU TPD, EU Medicinal Product and PMTA applications”

  • Ian Fearon

    Director of Tobacco Research Celerion

    Ian is a Director of Tobacco Research at Celerion, a provider of clinical research capabilities and expertise to the tobacco and e-cigarette industry. Prior to that, Ian was Principal Scientist and Head of Clinical Research at British American Tobacco's central research and development centre in Southampton, U.K. He specializes in the biological and psychological effects of nicotine, clinical studies to assess the biological effects of electronic cigarettes and tobacco heating devices, and the scientific basis for regulation.  Prior to working in the industry, Ian pursued an academic career as a Lecturer in Physiology at the University of Manchester and an Assistant Professor in Biology at McMaster University in Hamilton, Canada.  Ian is a highly-cited scientific researcher and writer, contributing to more than 50 peer-reviewed papers and book chapters which have generated over 2,200 citations.

  • Scott Fletcher

    Director of Analytical Services Hall Analytical

    Scott is the Director of Analytical Services at Crawford Scientific where he heads up their specialist MS based laboratory, Hall Analytical, in Manchester, UK.

    Hall Analytical has a long association with e-cigarette analysis and development with over 10 years experience of preforming analytical testing on the very early cigalike prototypes.

    Before this he spent many years working as a professional trainer and consultant in analytical chemistry and prior to that he worked in the pharmaceutical industry in the incredibly analogous field of developing dry powder inhalers!

    Scott sits on the Separation Science Committee of the Royal Society of Chemistry, of whom he is a Fellow, and on the Editorial Advisory Board of various Separation Science publications and is regular speaker at national and internal conferences. 

  • Judy E. Gibson

    Secretary General (CEO) INNCO (International Network of Nicotine Consumer Organisations)

    Since gaining her Brownie Wings in the 60’s, Judy has had an eclectic career including: WRAF Aircraft mechanic, drill instructor, restaurant manager, detective sergeant, MOD/MI5 gopher, Computer Consultant, twenty years in artiste management, theatre marketing/film programming and finally a Community Flood Consultant before reaching the zenith that is INNCO. A Jill of all trades and occasional mistress seems to cover it. A smoker since the invention of bike-sheds, Judy tried vaping about six years ago, reducing smoking but struggling with e-cigarette incarnations until, in 2015, technological improvements tipped the scales. Having finally eschewed cigarettes, she was astounded to discover that despite vaping being significantly safer, others were demanding draconian regulations and prohibition. Thus, a vociferous advocate for tobacco harm reduction was born. When not engaged in rebutting the latest vaping ‘research’ scare stories, overzealous state regulation or the latest calls for banning every e-liquid flavour except tobacco (the irony), she might be found nursing a large ‘Rakish Rhubarb Gin’, ambivalent to the rampaging brambles in her cottage garden.

  • Liam Humberstone

    Technical Director at Totally Wicked Product Design & Engineering at Independent British Vape Trade Association (IBVTA)

    Liam Humberstone is Technical Director at Totally Wicked Limited.  His involvement with standards and regulations for e-cigarettes and e-liquid started with a notorious legal challenge, but he has since worked collaboratively with regulators at UK National, European and other International levels.  His background is in design engineering and scientific research, and he has been involved in the e-cigarette industry since 2011.

  • Ian Jones

    Vice President Reduced-Risk Products Japan Tobacco International

    Ian Jones is the Reduced-Risk Products Vice President at Japan Tobacco International (JTI), based in Geneva, Switzerland.

    He joined JTI in 2006 from the University of Bath, UK, where he was a lecturer in Developmental Neuroscience at the Department of Biology and Biochemistry. Prior to this he held post-doctoral research positions at the Universities of Bath, Oxford and London, specializing in the anatomical neuropharmacology of nicotinic acetylcholine receptors. He holds a PhD in cell physiology, completed at Imperial College, London (1995).

  • Beryl Keeley

    Advertising Standards and Outreach Unit Manager Medicines and Healthcare products Regulatory Agency (MHRA)

    Beryl Keeley has a background in biochemistry and has worked in various areas in Government and previously in the pharmaceutical industry.  Beryl is currently Advertising Standards and Outreach Unit Manager at the Medicines and Healthcare products Regulatory Agency.  The Unit has responsibility for the regulation of medicines advertising in the UK and for production of Drug Safety Update and sits within the MHRA Vigilance and Risk Management of Medicines Division.  Beryl has recently completed a project to lead the UK implement of the Tobacco Products Directive notification scheme for e-cigarettes.  

  • Patricia I. Kovacevic

    General Counsel and Chief Compliance Officer Nicopure Labs LLC

    Patricia I. Kovacevic is the General Counsel and Chief Compliance Officer of Nicopure Labs LLC, a leading international e-liquid and vaping device manufacturer of U.S.- made Halo, Purity and eVo e-liquids. With extensive U.S. and international legal and regulatory experience, Kovacevic held senior legal and compliance positions at, among others, Philip Morris International and Lorillard. Prior to joining Lorillard she was a partner at Patton Boggs. Her expertise includes global nicotine, e-cigarette and tobacco regulation, compliance and all regulatory aspects of marketing/media communications, corporate affairs, criminal investigations, FCPA, trade sanctions, privacy and government affairs. Kovacevic serves on the board of directors of the Vapor Technology Association and on the advisory board of the Global Tobacco & Nicotine Forum. In the past she was a United Nations staff member, served on the U.N.’s Public-Private Partnership Commission and was also an adviser to various industry conferences. Kovacevic is admitted to practice in New York and before the Supreme Court of the United States. She holds a J.D. from Columbia Law School in New York and has completed the Harvard Business School “Corporate Leader” course. She is fluent in seven European languages. 

  • Neil McCallum

    CEO JAC Vapour

    Neil started his career by obtaining an engineering degree, followed by a Master’s in facilities management before joining Morgan Stanley at the age of 26. He eventually moved out of banking to join the Scottish Environment Protection Agency (Sepa) as Head of Facilities and Estates. His last post before joining JAC Vapour Ltd in October 2016 as CEO was as Managing Director of Critiqom Ltd where sales were lifted by 60% and profit by 50% during his time with the Company.

  • Willie McKinney

    Vice President Regulatory Sciences Altria Client Services

    Willie J. McKinney, Ph.D., D.A.B.T., serves as Vice President, Regulatory Sciences, for Altria Client Services (ALCS) in Richmond, Virginia. In this role, he leads a team that develops scientific evaluation and regulatory science strategies for Altria's family of companies.

    Dr. McKinney has held a variety of positions with increasing responsibilities within the Altria family of companies. He served as Senior Director, Product Integrity and Regulatory Reporting, where he led a team that develops scientific evaluation and regulatory submission strategies for Altria's family of companies; Director, Strategic Product Planning, where he provided operational and strategic support; Senior Manager, Cellular & Molecular Biology Group; and as a visiting scientist at the Institute for Biologische Forschung GmbH (INBIFO) in Köln, Germany.

    Before joining the Altria family of companies in 1998, Dr. McKinney held a variety of academic and research roles, including working as an Associate Research Scientist, Nelson Institute of Environmental Medicine, NYU Medical Center, Tuxedo, N.Y., and as a Graduate Research Assistant at the Center for Environmental Medicine and Lung Biology at the University of North Carolina at Chapel Hill. He also held Toxicology Intern and Research Assistant roles with several government agencies. Dr. McKinney is board certified in Toxicology by the American Board of Toxicology. He has published numerous professional articles related to his research and work, and has presented before various scientific organizations. He holds a BS degree in Biology from Xavier University, an MS in Biology from North Carolina Central University, and a PhD in Environmental Toxicology from the University of North Carolina at Chapel Hill. He serves on the Higher Achievement Board and on the Richmond Higher Achievement Advisory Board.

  • James Murphy

    Head of Biosciences British American Tobacco

    Full biographical details to come...

  • Mark Pawsey MP

    Chair of the All-Party Parliamentary Group on E-Cigarettes Member of Parliament for Rugby

    Mark was selected as the Conservative Parliamentary Candidate in Nuneaton for the 2005 General Election and slashed Labour's majority from 7500 to 2200 (a swing of 6.2% to the Conservatives). He was then selected for the newly formed Rugby constituency seat in 2007 and went on to secure a victory at the polls with a majority of exactly 6000 votes at the General Election in 2010. Mark was re-elected to serve the people of his home town in 2015 with an increased majority of 10,345. In 2017 Mark was re-elected as Member of Parliament for Rugby and Bulkington with over 50% of the vote.

    After the 2017 General Election, Mark has been elected to the Business, Energy and Industrial Strategy Select Committee which scrutinises the work of the Department for Business, Energy and Industrial Strategy. Mark was also elected by his Conservative colleagues to the 1922 Executive Committee, a a prestigious role within the Parliamentary Conservative Party.

    Mark is also a member of the All-Party Groups on Manufacturing, Micro-Businesses, Packaging, Small Business, Cycling, Speedway and Rugby Union and founded the All-Party Group for e-cigarettes. He has also recently founded the All-Party Parliamentary Group for District Councils.

  • Tim Phillips

    Managing Director ECigIntelligence

    The founder and managing director of ECigIntelligence, Tim is a UK-qualified attorney, having worked at the European Commission, BSkyB and Herbert Smith (an international law firm), AOL Europe, as director of public affairs at Betfair (IPO in 2010 valued at £1.5bn), and as a partner in a New York VC-funded start-up in the diamond sector. Tim holds a Postgraduate Diploma in Legal Practice from the University of Law, London and a Masters in Geology from Oxford University.

  • Dr. Lorraine Rusch

    President High Point Clinical Trials Center

    Dr. Rusch is a highly experienced drug development scientist and executive, specializing in early clinical research and development services. She has significant drug development expertise from the biotechnology industry and is a leader in the contract research organization sector, known for expanding research capabilities and creating unique service offerings to the biopharma industry.

  • Tanvir Walele

    Director - Scientific Affairs Fontem Ventures

    Tan is a European Registered Toxicologist with significant experience in risk assessment and risk management, in-vitro toxicity models and clinical research. At Fontem Ventures he is responsible for a team of scientists supporting non-tobacco, next generation products and heads up their stewardship function which includes liaising with external advisors, engagement and regulatory authorities and providing advice on and management of product testing strategies. In addition Tan is responsible for the compilation and provision of robust & substantive scientific information in support of products as required by regulations worldwide, to ensure their approval by government authorities. This includes the provision of dossiers through regulatory frameworks such as EUTPD, Medicinal Licensing and US FDA.

    Tan's qualifications include: European Registered Toxicologist, ERT; Toxicology, MSc; Medical Biochemistry, BSc

  • Shaun Wedgewood

    Technical Director EL-Science

    Shaun is an analytical chemist with over 20 years’ experience working within some of the world’s top chemical companies.

    Shaun began his career developing flavour and fragrance concentrates and additives for a company now known as Fruitarom. He then worked across a range of chemical companies before settling down with InterTek and British Petroleum (BP) for a five year period.

    Seeking a new challenge and noting legislative changes in the way the UK handles its hazardous waste, Shaun entered discussions with an innovative newly formed company called Augean in 2007. Shaun was employed at a senior management level to create and implement the UK’s first dedicated, accredited hazardous waste laboratory. As well as offering in-depth analytical facilities with some of the most advanced analytical instrumentation commercially available, the laboratory team also developed Augean’s sustainable process technology allowing Augean to safely manage some of the UK’s most difficult hazardous waste streams, including low level radioactive material.

    Shaun then turned his attention to electronic cigarettes, incorporating i-Vapo Limited with his business partner, Andrew, in May 2013.

  • Richard Young

    Principal Toxicologist and Managing Director bibra toxicology advice and consulting

    Richard is a RSB/BTS and European Registered Toxicologist (ERT) and has been working as a desk-based toxicologist at bibra for 15 years. His special interests include the pragmatic application of risk assessment methodology to mammalian toxicity data sets, in order to derive robust conclusions on toxicological acceptability of exposures and on health risks to exposed populations. In recent years he has been helping companies assess the potential human health effects of Non-Tobacco Nicotine Delivery Devices (NTNDDs). This has included assisting in the production of toxicity monographs on over 300 e-liquid ingredients, assisting with the EU CLP classification of e-liquids, and proposing toxicologically tolerable levels for key e-liquid ingredients and e-cig emissions (e.g. several aldehydes).